Related Experiment Videos
Radiotracer-based strategies to image angiogenesis
R H Haubner1, H J Wester, W A Weber
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. R.Haubner@lrz.tum.de
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)
|August 5, 2003
Summary
Developing new radiotracers to monitor tumour angiogenesis is crucial for effective cancer therapy. While some methods show promise in animal models, clinical translation for patient visualization remains a challenge.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Imaging
Background:
- Tumour-induced angiogenesis is vital for cancer progression.
- Monitoring anti-angiogenic therapies is challenging with conventional methods.
- Radiotracer development offers a potential solution for therapy assessment.
Purpose of the Study:
- To review current radiotracer-based strategies for monitoring tumour angiogenesis.
- To evaluate the efficacy of different radiotracers in preclinical models.
- To identify challenges and future directions for clinical translation.
Main Methods:
- Investigated radiolabelled inhibitors of matrix metalloproteinases.
- Examined radiolabelled single chain fragments targeting fibronectin ED-B domain.
- Focused on radiolabelled antagonists of integrin alpha(v)beta(3) using various isotopes.
Main Results:
- Matrix metalloproteinase inhibitors showed in vitro promise but failed in vivo validation.
- Fibronectin ED-B targeted tracers demonstrated selective tumour vasculature accumulation in mice.
- Integrin alpha(v)beta(3) antagonists showed high affinity and selectivity, enabling non-invasive monitoring in murine models.
Conclusions:
- Radiotracer approaches show potential for monitoring tumour angiogenesis in preclinical studies.
- Further research is needed to translate these findings into clinical applications for patient imaging.
- Successful visualization of tumour angiogenesis in patients requires further development and validation.